Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

41.7%

30 terminated/withdrawn out of 72 trials

Success Rate

53.1%

-33.4% vs industry average

Late-Stage Pipeline

4%

3 trials in Phase 3/4

Results Transparency

68%

23 of 34 completed trials have results

Key Signals

3 recruiting23 with results25 terminated5 withdrawn

Enrollment Performance

Analytics

Phase 2
20(37.0%)
Phase 1
14(25.9%)
N/A
14(25.9%)
Phase 3
3(5.6%)
Early Phase 1
3(5.6%)
54Total
Phase 2(20)
Phase 1(14)
N/A(14)
Phase 3(3)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (72)

Showing 20 of 72 trials
NCT07436793Phase 2Not Yet Recruiting

Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial

Role: lead

NCT06207864Not ApplicableRecruiting

Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing

Role: lead

NCT06260332Not ApplicableActive Not Recruiting

Physical Activity Intervention for the Improvement of Pain in Young, Hispanic Breast Cancer Survivors

Role: lead

NCT04259762Not ApplicableCompleted

Enhancing Cancer Prevention and Control Pathways-Native Health Initiative

Role: lead

NCT02571725Phase 1Active Not Recruiting

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

Role: lead

NCT02470299Not ApplicableCompleted

Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients

Role: lead

NCT03568448Active Not Recruiting

Monitoring Response to Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Using High-speed MR Spectroscopic Imaging

Role: lead

NCT03953443Completed

Expression & Epigenetic Silencing of MicroRNA for Predicting Therapeutic Response and Prognosis of HPV-negative HNSCC

Role: lead

NCT00322894Completed

Expanded Breast Cancer Registry and Tissue Repository

Role: lead

NCT02147418Completed

Exosome Testing as a Screening Modality for Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma

Role: lead

NCT02105545Not ApplicableCompleted

Genome Sequencing of Human Cancer Tissues

Role: lead

NCT03977402Recruiting

Total Cancer Care Protocol: A Lifetime Partnership With Patients Who Have or May be at Risk of Having Cancer

Role: lead

NCT02753790Not ApplicableCompleted

Whole Brain Radiation Using IMRT for Patients With Brain Metastases

Role: lead

NCT03943316Recruiting

Laboratory Study of Cancer & Immune Cells in Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies

Role: lead

NCT03941782Unknown

Compassionate Use of BYL 719 Alpelisib

Role: lead

NCT02580981Not ApplicableTerminated

Acute Lymphoblastic Leukemia Therapies Informed by Genomic Analyses

Role: lead

NCT01821833Not ApplicableCompleted

Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel

Role: lead

NCT05176743Not ApplicableCompleted

Food Insecurity in Oncology

Role: lead

NCT03979729Completed

Breast Cancer Screening for Underserved Women: Comparing Outcomes and Lowering Recall Rates With 3D- vs. 2D-mammography

Role: lead

NCT01032850Phase 2Terminated

Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma

Role: lead